| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
May 2020
|
 |
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
The true significance of many medical or technical achievements often only emerges in times of crisis. That is now the case with the coronavirus pandemic.
On the one hand, all citizens now realize the vital importance of a well-developed and functioning health system. On the other hand, more and more people are realizing that technical innovations in the fields of pharmaceuticals (vaccines, medicines), medical technology (ventilators), diagnostics (COVID-19 tests) and other healthcare/life science sectors are making a particularly important contribution to tackling a crisis of the kind we are currently experiencing.
We have been investing in companies in medical technology, life science, diagnostics and digital health for 27 years. German and international investors in the five SHS funds to date include professional pension insurers, retirement funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team, among others. Investors who invest in innovative healthcare firms through SHS funds are helping tackle current and future crises. Their investments show that, when making an investment decision, responsibility and return do not have to be mutually exclusive.
The goal of our portfolio companies is to improve and even save patients’ lives. We are pleased that our investors are promoting the socially responsible investment approach of SHS. Our presentation of selected SHS portfolio companies here is meant to illustrate just how important innovations in the healthcare sector are for us all.
Detailed information on SHS can be found here: https://www.shs-capital.eu/en/
We wish you an exciting read.
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
|
| |
| |
|
Topics
|
| |
| • |
BVK interview Swantje von Massenbach with André Zimmermann
|
| |
|
|
|
| • |
Ultra-fast, on-site diagnostics of coronavirus as a lifesaver
|
| |
|
|
| • |
Identifying patients with unknown conditions of high risk
|
| |
|
|
| • |
Psychological assistance in times of social distancing
|
| |
|
|
| • |
Biotech tools to support vaccine development
|
| |
|
|
| • |
Secure packaging and transportation of life-saving vaccines
|
| |
|
|
| • |
Internationally approved innovation for ventilatory support from Germany
|
| |
|
|
| • |
Clever tools to relieve nursing staff in the clinic
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
BVK interview Swantje von Massenbach with André Zimmermann |
|
|
| |
| |
|
|
Impact Investing, sustainable investing, ESG: more and more investors are attaching importance to socially responsible investing. SHS partner Dr. André Zimmermann explains SHS' approach and why yield and responsible investing need not be a contradiction in terms in a TV interview with Swantje von Massenbach.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Ultra-fast, on-site diagnostics of coronavirus as a lifesaver |
|
|
| |
| |
|
|
Diagnostics
GNA Biosolutions GmbH (SHS IV Fund)
GNA Biosolutions GmbH has an important role to play in combating the pandemic with its ultra-fast coronavirus test, which is performed on-site.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2010
Business purpose: Development, production and distribution of molecular diagnostic tests (POC/PON) and devices that are at least 10 times faster based on laser PCR technology to accelerate time-critical diagnoses (e.g. in case of infections) for the benefit of the patient
Products: Pharos 400, PharosV8
Location: Munich (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Identifying patients with unknown conditions of high risk |
|
|
| |
| |
Diagnostics
ndd Medizintechnik AG (SHS IV Fund)
Nuanced lung diagnostics for high-risk patients plays an important role in the battle against COVID-19. ndd Medzintechnik AG has the right technology.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 1996
Business purpose: Development, production, and distribution of diagnostic products in the area of respiratory disorders, mainly COPD and asthma
Products: Spirometer (EasyOne/EasyOne Air), different devices for lung function testing (EasyOne Pro/EasyOne Pro Lab; Easy on PC)
Locations: Zurich (CH) and Andover (USA) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Psychological assistance in times of social distancing |
|
|
| |
| |
|
|
Digital healthcare
Selfapy GmbH (SHS V Fund)
The clinically proven app by Selfapy GmbH offers quick assistance to people in acute psychological crises without long waiting times, even in the era of the coronavirus.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2016
Business purpose: Provider for online therapies for mental health
Products: Online therapy programs that are based on cognitive behavioral therapy, for stress symptoms, depression, and anxiety and eating disorders
Location: Berlin (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Biotech tools to support vaccine development |
|
|
| |
| |
Pharmaceutical services
c-LEcta GmbH (SHS III Fund)
Denarase, the artificial enzyme by c-LEcta GmbH, is used by international pharmaceutical and biotech companies in the development of drugs and vaccines.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2004
Business purpose: Development, optimization and production of high-quality enzymes and microbial strains for industrial biotechnology applications in food, feed, pharma and chemistry
Products: Industrial enzymes: For food and animal feed and for the optimized production of pharmaceuticals; bio-chemicals: food & feed supplements, APIs, monomers
Location: Leipzig (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Secure packaging and transportation of life-saving vaccines |
|
|
| |
| |
|
|
Pharmaceutical services
Single Use Support GmbH (SHS V Fund)
Even if everything has to be done quickly in the coronavirus crisis: medical fluids need to be absolutely secure and protected during handling. Single Use Support has the right products for this.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2016
Business purpose: The company develops, manufactures and sells secondary transport equipment and machines for freezing, transporting and defrosting active biopharmaceutical ingredients.
Products: stable and manipulation-proof tray for the transport of all disposable single use bags (RoSS); machines for the fully automatic filling and emptying of single use bags (RoSS.FILL); a freeze-thaw platform
Location: Kufstein (A) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Internationally approved innovation for ventilatory support from Germany |
|
|
| |
| |
Medical technology
TNI Medical AG (SHS III Fund)
Non-invasive ventilatory support by TNI plays a helpful role in the treatment of COVID-19 patients and persons with COPD.
|
|
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 2007
Business purpose: development, production and distribution of diagnostic and therapeutic devices for breathing support for home-care and clinical use
Products: clinical and home respirators TNI® softFlow 50
Location: Würzburg (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
Clever tools to relieve nursing staff in the clinic |
|
|
| |
| |
|
|
Medical technology
Novo Klinik-Service GmbH (SHS IV Fund)
Safe and easy-to-use products for the fixation and stabilization of endotracheal tubes in invasively ventilated patients.
|
|
|
|
|
|
| |
|
|
| |
| |
|
|
| |
KEYFACTS |
|
| |
|
|
| |
Year established: 1987
Business purpose: Development, production and sales of medical technical products
Products: app. 100 products: fixations and pads for the intensive care, anaesthetic and nursing sectors
Location: Kerpen (D) |
|
| |
|
|
|
|
|
| |
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, digital health, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland, Scandinavia, Benelux |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100m; investment amount:
€ 2-30m, with a co-investor from the SHS-network up to € 60m |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
|
|
|
| |
|
|
| |
The newsletter is published by SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
| |
|
|
| |
Bismarckstrasse 12 | 72072 Tuebingen | Germany | www.shs-capital.eu
Tel +49 7071 9169-0 | Fax +49 7071 9169-190
|
|
| |
|
|
| |
|
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH
Design and technical realisation: UNIBRAND GmbH
|
|
To unsubscribe the newsletter, please click here. If you like us to delete your data, please send an email with the subject „data deletion“ to tuebingen@shs-capital.eu.
|
|
|
| |
|
|
|
|
| |
|
.jpeg "BVK Expertentalk")
.jpeg "Pharos400_DNA_Analyser_1.jpg")
.jpeg "ndd EasyOne Pro")
.jpeg "CLE.jpg")
.jpeg "1911_RoSS_Shell_2.jpg")
.jpeg "TNI_softflow50_Detail.jpg")
.jpeg "Novo_Klinik-Service_Main-Lock_4.jpg")